TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00419757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide/formoterol (SYMBICORT) pMDI
Description: SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide HFA pMDI
Description: Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily
Study: NCT01842269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil 500mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil 250mg
Study: NCT01726296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Complete an educational intervention based on NCCN guidelines and disease-specific issues related to survivorship care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical chart review
Description: Complete patient medical chart audit
Study: NCT03983408

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Korean Red Ginseng
Description: Participants are provided with 2 Korean Red Ginseng extract tablets twice a day for total 24 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, made of corn starch and cellulose, are manufactured to mimic KRG tablets. Participants are parovided with 2 placebo tablets twice a day for first 12 weeks, following Korean Red Ginseng extract tablets twice a day for another 12 weeks.
Study: NCT02843009

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise Training
Description: Resistance exercise will involve 2 sessions per week for 18 weeks. Each session will involve participants carrying out the following exercises: calf press, leg press, leg extension and leg curl

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Exercise Training
Description: Resistance exercise will involve 2 sessions per week for 18 weeks. Each session will involve participants carrying out the following exercises: calf press, leg press, leg extension and leg curl

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplementation
Description: Participants randomised to either 3g/day of fish oil or safflower oil for 18 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Supplementation
Description: Participants randomised to either 3g/day of fish oil or safflower oil for 18 weeks
Study: NCT02305602

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VentriGel
Description: VentriGel will be injected via MyoStar catheter after NOGA mapping
Study: NCT03360448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad5.hAC6
Description: 1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery
Study: NCT02654652

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Symbiotic
Description: Intervention will consist of the adminitration of symbiotic product twice a day during seven days after surgical treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Intervention will consist of the adminitration of placebo product twice a day during seven days after surgical treatment
Study: NCT03381339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oscillating rotating power toothbrush
Description: a battery powered oscillating rotating toothbrush will be used for twice daily regular home dental hygiene
Study: NCT03704168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRYOABLATION
Description: The SeedNet® System induces freezing and thawing at the tip of the needle. These freezing and thawing processes are based on the Joule-Thomson effect. The unique technology of the SeedNet® System provides extremely rapid freeze and thaw operations. The system's software controls the flow of gases from the gas sources, through the manifold, to the needle and probe tips. The system can immediately switch from the freezing process to the thawing process, after which the needle can be released. This device is an FDA-cleared medical device. This IDE application is to allow for use of the commercially available device in a new clinical indication, namely cryoablation of the submandibular glands.
Study: NCT01623193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: All-blood cardioplegia
Description: The treatment group will receive all-blood cardioplegia for myocardial protection during surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard cardioplegia
Description: This arm will receive standard 4:1 cardioplegia for myocardial protection during surgery
Study: NCT04224402

Intervention type: DRUG
Group type: OTHER
Intervention: mFOLFORINOX
Description: Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
Study: NCT00283244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: given IV
Study: NCT02628028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3337641
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3337641
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3337641
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3337641
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3337641
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3337641
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT03242967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: subcutaneous or intravenous
Study: NCT02731144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peptamen intense

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Novasource senior
Study: NCT00494520

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Errorful training condition
Description: Errorful training condition: Participant saw a picture and named it without any cues. If an error was produced, the cue with the least amount of information was provided (e.g. for pumpkin, pu). Cues with increasing information were provided until the picture was correctly named (e.g. for pumpkin: pump, pumpki, then pumpkin). Once the correct name was provided, the trial ended.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Errorless training condition
Description: Errorless learning (EL) condition: Participant saw a picture with its name, and repeated the word. The participant continued to name the picture as the auditory cues provided less and less of the word (e.g. for banana she would hear banan, bana then ba and finally no cue). If an error was produced at any stage, the whole word was presented, the participant repeated it, and the trial ended.
Study: NCT03172598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 low dose
Description: Capsule
Study: NCT00673621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin Inhalation Powder
Description: 3.0 of human insulin. single dose cartridges filled with 5 or 10 mg of Technosphere Inhalation Powder, containing 15 or 30 u of insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol (Albuterol)
Description: 2 puff = 200 mcg total dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine chloride
Description: 5mls of methacholine; diluent sodium chloride 0.9%; formulation methacholine chloride in sodium chloride 0.9%
Study: NCT00785811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine aspartate (Targifor)
Description: 3g of L-arginine taken orally in a single daily dose for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo L-arginine aspartate (Targifor)
Description: Placebo of L-arginine taken orally in a single daily dose for 8 weeks
Study: NCT02302170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H. pylori vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02352519

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UGBRSB
Description: Under sterile conditions,the posterior rectus sheath will be identified by ultrasound, and an insulated 22 gauge 50 mm needle inserted till the tip is seen to be directly between the rectus abdominis muscle and the posterior rectus sheath. Bupivacaine 0.25% (0.2 ml/kg with maximum 5 ml in each side) will be injected observing the spread on the ultrasound image.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Infiltration
Description: In those patients randomized to the LAI group, the surgeon will perform infiltration of 0.5 ml/kg of 0.25% bupivacaine (maximum, 10 ml) around the incision
Study: NCT00315991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood Glucose Awareness Training for Parents
Study: NCT02290080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: see arm description
Study: NCT00438672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Injection
Description: Injection without steroid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Injection
Description: Injection without steroid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Injection
Description: Injection without steroid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid (dexamethasone) Injection
Description: Injection with steroid (dexamethasone)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid (dexamethasone) Injection
Description: Injection with steroid (dexamethasone)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid (dexamethasone) Injection
Description: Injection with steroid (dexamethasone)
Study: NCT01035567

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid revascularization
Description: First stage: implantation of the internal mammary artery into LAD in MIDCAB/TECAB procedure Second stage: PCI with drug eluting stents in other coronary arteries qualified for revascularization within 36 hours after surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Bypass Grafting
Description: Coronary artery bypass grafting with sternotomy on or off the pump at discretion of the operator.
Study: NCT02409524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloVax
Description: Personalized anti-cancer vaccine (injection of AlloStim followed immediately by the injection of CRCL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: AlloStim (ID) injection AlloStim (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRCL
Description: Autologous tumor-derived chaperone protein mixture
Study: NCT03203187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mango
Description: 330 grams (2 cups) of daily mango intake for two weeks, one cup in the morning, the other in the evening

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: No mango intake for two weeks.
Study: NCT02929277

Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling, skin prick tests, assesment of atopic dermatitis, questionnaires
Study: NCT04851353

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GT+VC
Description: Gentle touch and verbal comfort,

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GT+VC
Description: Gentle touch and verbal comfort,

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GT+VC
Description: Gentle touch and verbal comfort,

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smell
Description: Smell breast milk

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smell
Description: Smell breast milk

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taste
Description: Taste breast milk
Study: NCT03453853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitral Loop Cerclage Annuloplasty
Description: Atrial Functional mitral regurgitation Response In mitral loop Cerclage Annuloplasty
Study: NCT02856100

Intervention type: DRUG
Intervention: 18F DCFPyL- Radiopharmaceutical
Study: NCT01941147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed ELF-MF
Description: (75 Hz, 1,8 mT)
Study: NCT00710905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof ReSTOR Aspheric IOL models SN6AD1 and SN6AD3
Description: Contralateral implantation of AcrySof ReSTOR +3 Intraocular Lens (IOL) in one eye, AcrySof ReSTOR +4 IOL in the other eye following cataract removal.
Study: NCT04944745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release
Description: Moderate pressure manual treatment to the pectoral fascia.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Soft-touch Control
Description: No pressure manual treatment to the pectoral fascia.
Study: NCT04765332

Intervention type: OTHER
Intervention: DLQI and PSO-TARGET QoL grid
Description: At inclusion visit, and after 3 and 12 months, the patient will fill a patient questionnaire containing DLQI and PSO-TARGET QoL grid
Study: NCT02957032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F16IL2
Description: All patients first receive an initial run-in dose of 30 Mio IU of F16IL2 on day 1 and escalating doses of F16IL2 on day 1, 8, 15 and 22.~Treatment will be repeated every 28 days for up to three cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Patients will be treated with cytarabine (5 mg twice daily s.c. for 10 days). Treatment will be repeated every 28 days for up to three cycles.
Study: NCT03545802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-HIT
Description: Participants completed 6 weeks of home-based high-intensity interval training 3 times per week
Study: NCT00518895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine plus Genasense
Description: Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus Genasense group will receive Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the Genasense infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dacarbazine plus placebo
Description: Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus placebo group will receive placebo (that is, locally available commercial 0.9% Sodium Chloride Injection) by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the placebo infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
Study: NCT01147536

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSPPC-96
Study: NCT03636529

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tart cherry juice
Description: Participants randomized to consume for 4-weeks either placebo beverage or single-strength tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage for 4 weeks to account for timing and order effects.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
Study: NCT04311710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENHANZE (rHuPH20)
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENHANZE (rHuPH20)
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENHANZE (rHuPH20)
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified Dose on Specified Days
Study: NCT00490152

Intervention type: BEHAVIORAL
Intervention: Automated diary system
Description: Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study.

Intervention type: BEHAVIORAL
Intervention: Automated diary system
Description: Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study.

Intervention type: BEHAVIORAL
Intervention: Automated diary system
Description: Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study.
Study: NCT04668040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle energy technique
Description: Muscle energy technique for illiopsoas, rectus femoris, erector spinae \& hamstrings muscles duration of contraction was 10 sec, rest interval was 5 sec, stretch duration was 30 sec, number of repetition of stretch was 5, number of set was 1, frequency per week was 3

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Stretching exercises for illiopsoas, rectus femoris, erector spinae \& hamstrings muscles duration of stretch was 15 sec, rest interval was 5 sec, number of repetition was 5, number of set was 1, frequency per week was 3
Study: NCT00558077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin plus clomiphene citrate
Description: Metformin administration will start from 3rd day of a P-induced withdrawal bleeding with a dose of 850 mg (1 tablet daily) and increasing the dosage after one week up to 1700 mg/day (two tablets daily). Clomiphene citrate CC will be administered for five days beginning on cycle day 3rd of a P-induced withdrawal bleeding using a starting dose of 50 mg daily. If ovulation will not occur, the dose will be increased by 50 mg in successive cycles until the ovulation will be achieved or up to a maximal dose of 150 mg daily.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ovarian drilling
Description: Laparoscopic ovarian drilling will be performed as follows: according to ovary size three to six punctures will be performed at each ovary inserting an insulated needle cautery of 36 mm perpendicularly as possible to the ovarian surface with a cutting current of 100 watt power. Then, the needle will be activated for 2-3 seconds at each point using a coagulating current of 40 watt power. At completion of the procedure, the ovarian surface will be washed with a crystalloid solution and all injured areas will be completely covered with hyaluronic acid gel.
Study: NCT03435302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide Plus Cisplatin
Description: Temozolomide is the oral analog of dacarbazine (DTIC), shows potential advantages over dacarbazine.~Cisplatin is an agent that can potentially enhance the activity of temozolomide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-Dose IFN-a2b
Description: Interferon belongs to the large class of glycoproteins known as cytokines.
Study: NCT03172598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 low dose
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 low dose
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 middle dose
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 middle dose
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 middle dose
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 high dose
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 high dose
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 high dose
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule
Study: NCT04418362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Description: A home-based self-administered neurofeedback intervention taking place 4-6 times per week for 8 weeks.
Study: NCT02007317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oshadi D & Oshadi R
Description: Anti tumor agents